Biotech giant Bristol-Myers Squibb Company BMY is scheduled to report first-quarter 2025 results on April 24, before market ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in ...

We're going to check out a few of the best picks from our screener tool. Overview: Tenable Holdings, Inc. offers cyber exposure management solutions across various regions including the Americas ...

First Mining Gold Corp. (TSE:FF – Get Free Report) rose 6.3% during mid-day trading on Tuesday following insider buying activity. The company traded as high as C$0.13 and last traded at C$0.13.

US pharma major Bristol Myers Squibb (NYSE: BMY) has received full approval from the US Food and Drug Administration for the use of Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line ...

After gaining 5.78% in January, the BioWorld Cancer Index reversed course, falling 4.74% year-to-date by the end of March. The index’s movement has closely tracked broader market trends. The Nasdaq ...

Since Feb 19, there have been as many big biotech gainers as losers. A couple, such as 2seventy bio, which is developing a therapy for blood cancer, leapt from the bottom 100 to the top. There may be ...

Since February 19th, there have been as many big biotech gainers as losers. A couple, like 2seventy Bio, which is developing a therapy for blood cancer, leapt from the bottom 100 to the top.

American pharma giant Bristol Myers Squibb (BMS) kicked off the month with its $286 million acquisition of U.S.-based 2seventy bio. BMS will begin a tender offer to acquire all outstanding shares of ...

Overview: 2seventy bio, Inc. is a cell and gene therapy company dedicated to researching, developing, and commercializing cancer treatments in the United States, with a market cap of $259.07 million.